Brought to you by 
Glenmark signs royalty deal with Paul Capital Partners
13 Sep 2018
Executive Summary
Glenmark Pharmaceuticals Ltd. (developing drug candidates for dermatological, gynecological, and metabolic conditions) has signed a royalty deal with Paul Capital Partners (PCP) covering 16 therapeutics for dermatological conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Financing
- Other
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glenmark signs royalty deal with Paul Capital Partners
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice